Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Last trade$1.39
Day change-$0.095 (-6.42%)
Day range$1.37 – $1.53
Volume316,575
Market cap$42M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$41.89M
Price / earnings
—
Price / book
2.22×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.54×
Profitability
Earnings per share
-$1.26
Return on assets
-90.25%
Return on equity
-189.58%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.51×
Current ratio
3.43×
Quick ratio
3.43×
Cash ratio
3.11×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$36.99M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ELTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$3.56M
$3.62M
$3.85M
$3.76M
$3.01M
$3.09M
$2.96M
$2.77M
Research and development
$4.89M
$6.81M
$6.76M
$5.08M
$5.04M
$7.01M
$7.78M
$10.71M
Total operating expenses
$8.45M
$10.43M
$10.6M
$8.84M
$8.05M
$10.09M
$10.74M
$13.48M
Operating income
-$8.45M
-$10.43M
-$10.6M
-$8.84M
-$8.05M
-$10.09M
-$10.74M
-$13.48M
Interest expense
-$413K
-$410K
-$407K
-$337K
-$426K
-$194K
-$176K
-$234K
Income before taxes
-$7.92M
-$8.22M
-$11.82M
-$7.72M
-$10.08M
-$10.56M
-$11.21M
-$14M
Income taxes
$55K
$0
$0
$0
$0
$0
$0
$0
Net income
-$7.98M
-$8.22M
-$11.82M
-$7.72M
-$10.08M
-$10.56M
-$11.21M
-$14M
Net income attributable to common shareholders
-$7.98M
-$8.22M
-$11.82M
-$7.72M
-$10.08M
-$10.56M
-$11.21M
-$14M
EBITDA
-$8.42M
-$10.39M
-$10.56M
-$8.79M
-$8M
-$10.04M
-$10.68M
-$13.39M
Basic earnings per share
-$0.30
-$0.43
-$0.65
-$0.50
-$0.60
-$0.66
-$0.87
-$1.02
Diluted earnings per share
-$0.30
-$0.43
-$0.65
-$0.50
-$0.60
-$0.66
-$0.87
-$1.02
Recent news
Company coverage with links to the original publishers.
Over 200 companies are advancing cancer vaccine development with 200+ pipeline candidates in clinical trials. Recent positive Phase III results for intismeran autogene (mRNA-4157) in melanoma and encouraging data for TG4050 in head and neck cancer are driving momentum. However, challenges including clinical efficacy uncertainties, manufacturing complexity, high production costs, and patient selection barriers remain obstacles to broader commercialization.
Elicio Therapeutics announced that its CEO Robert Connelly and Chief Scientific Officer Pete DeMuth will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The clinical-stage biotech company is developing next-generation immunotherapies for KRAS-driven cancers, with its lead program ELI-002 7P targeting the most common KRAS mutations found in approximately 25% of solid tumors.
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech company, announced a registered direct offering of 4.38 million shares expected to raise approximately $15 million gross proceeds. The company plans to use the funds to support Phase 1 clinical development of ELI-002 7P in metastatic pancreatic cancer, pipeline advancement, and general corporate purposes. The offering is expected to close on or about July 6, 2026.
Elicio Therapeutics (ELTX), a clinical-stage biotech company developing immunotherapies for KRAS-driven cancers, was added to the Russell 2000 and Russell 3000 indexes as of June 26, 2026. The company is advancing its lead candidate ELI-002 7P, an off-the-shelf cancer immunotherapy targeting common KRAS mutations. However, the Phase 2 AMPLIFY-7P trial did not meet its primary endpoint of disease-free survival, prompting Elicio to refine its Phase 3 development strategy and initiate a Phase 1 study in metastatic pancreatic cancer.
Elicio Therapeutics announced that its Phase 2 AMPLIFY-7P study of ELI-002 7P did not meet the primary disease-free survival endpoint in the intent-to-treat population for adjuvant pancreatic cancer. However, post-hoc analyses showed promising results in the R0 resected patient subgroup (84% of enrolled patients) with a hazard ratio of 0.65 (p=0.048). Strong correlations between mutant KRAS-specific T cell responses and improved outcomes supported the drug's biological activity. The company plans to refine its Phase 3 strategy focusing on R0 resected patients with extended dosing, pending financing.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.